16s RRNA, Microbiome, Pancreatic Neoplasms
Conditions
Keywords
fecal microbiome, oral microbiome, pancreatic neoplasms, 16s rRNA
Brief summary
Significant gaps exist in understanding the gastrointestinal microbiota in patients with pancreatic cancer (PCA) versus benign or low-grade malignant pancreatic tumors (NPCA). This study aimed to analyze these microbiota characteristics and explore their potential use in distinguishing malignant pancreatic lesions.
Detailed description
In the past decade, microbiome research has rapidly progressed, revealing the critical roles of fecal and oral microbiota in maintaining internal homeostasis. Studies employing 16S rRNA and metagenomics have highlighted dysbiosis of the fecal and oral microbiota as closely linked to PCA development and progression. However, significant gaps exist in understanding the fecal and oral microbiota in patients with pancreatic cancer (PCA) versus benign or low-grade malignant pancreatic tumors (NPCA). This study aimed to analyze fecal and oral microbiota characteristics, and to establish classifiers to discriminate PCA from NPCA, providing a reference for early clinical identification of malignant tumors.
Interventions
DIAGNOSTIC_TEST16s rRNA or shotgun metagenomics
16s rRNA or shotgun metagenomics on oral and fecal samples
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with a pancreatic tumor detected via imaging with no prior treatment before sample collection * Patients volunteer to provide oral and fecal samples
Exclusion criteria
* Current or previous diagnoses of (a) other malignancies, (b) infectious diseases, (c) oral or gastrointestinal disorders (d) psychiatric or neurodegenerative disorders * Specific medical procedures or interventions within defined periods, including (a) antibiotic, hormone therapy, or immunosuppressant within the past three months, (b) gastrointestinal reconstructive surgery within the past three months, (c) frequent use of cathartics, antidiarrheals, or therapeutic doses of probiotics within the past month, (d) oral or gastrointestinal examinations within the past three days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the accuracy of the diagnostic classifier | From enrollment to the end of treatment at 8 weeks | we used random forest algorithm to construct oral and fecal microbiome classifiers to discriminate PCA and NPCA. AUC value was used to evaluate the efficacy of the classifiers |
Countries
China
Outcome results
None listed